Linked Life Data

20102969

Source:http://linkedlifedata.com/resource/pubmed/id/20102969

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1 Suppl
pubmed:dateCreated
2010-1-27
pubmed:abstractText
The renin-angiotensin system (RAS) plays key roles throughout the cardiovascular continuum, and blockade of this system--either through angiotensin-converting enzyme (ACE) inhibition or through angiotensin II type 1 (AT(1)) receptor antagonism--now occupies a central place in the management of cardiovascular disease (CVD). Understanding of the RAS has expanded in recent years with the identification of new pathways for formation of angiotensin II and novel effector peptides, such as angiotensin-(1-7), which may constitute new therapeutic targets. A substantial proportion of the benefits of ACE inhibitors, including vasodilation, improvements in endothelial function, and inhibition of cell proliferation, appear to be attributable to decreases in angiotensin II and increases in bradykinin. In addition, however, there is evidence that other mechanisms, such as modulation of ACE signaling, may also contribute. Angiotensin receptor blockers (ARBs) selectively block AT(1) receptors and allow unopposed stimulation of AT(2) receptors, with potentially beneficial vasodilatory, anti-inflammatory, and antiproliferative effects. As a result, these agents share many of the clinical benefits of ACE inhibitors. Both ACE inhibitors and ARBs have been shown to exert multiple antiatherogenic actions, and to reduce clinical events in high-risk participants; their use is recommended in current guidelines for the secondary prevention of CVD.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
1879-1913
pubmed:author
pubmed:copyrightInfo
Copyright 2010. Published by Elsevier Inc.
pubmed:issnType
Electronic
pubmed:day
4
pubmed:volume
105
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
10A-20A
pubmed:meshHeading
pubmed:year
2010
pubmed:articleTitle
Progression of cardiovascular damage: the role of renin-angiotensin system blockade.
pubmed:affiliation
Clinical Trials Service Unit, Division of Cardiology, Department of Medicine, University of Washington School of Medicine, Seattle, Washington, USA. jeffprob@u.washington.edu
pubmed:publicationType
Journal Article, Review, Research Support, Non-U.S. Gov't